Here’s what you should know:
1. Lumendi’s DiLumen EIP is approved in the U.S., Europe and, most recently, Hong Kong, China.
2. A Hong Kong, China-based Chinese University of Hong Kong physician recently completed the first procedure with EIP in Asia.
3. Lumendi CEO Peter Johann, PhD, said, “The growing, extensive use of DiLumen validates our goal of shifting the paradigm for colon disease intervention from the traditional surgical approach to a truly minimally invasive one that utilizes novel endolumenal-based technology. This shift will increase safety and patient recovery time as well as significantly reduce costs.”
More articles on gastroenterology:
Drs. Steven Matulis, Douglas Morgan, & more: 6 GI physicians making headlines
North Carolina finalizes plan that could spur ASC, hospital developments — 5 takeaways
Vizinet awards 5 Ambulatory Care Quality and Accountability awards — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
